Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Increased circulating soluble LR11 in patients with acute coronary syndrome.

Ogita M, Miyauchi K, Dohi T, Tsuboi S, Miyazaki T, Yokoyama T, Yokoyama K, Shimada K, Kurata T, Jiang M, Bujo H, Daida H.

Clin Chim Acta. 2013 Jan 16;415:191-4. doi: 10.1016/j.cca.2012.10.047. Epub 2012 Nov 2.

PMID:
23127357
2.

Circulating soluble LR11, a novel marker of smooth muscle cell proliferation, is enhanced after coronary stenting in response to vascular injury.

Ogita M, Miyauchi K, Jiang M, Kasai T, Tsuboi S, Naito R, Konishi H, Dohi T, Yokoyama T, Okazaki S, Shimada K, Bujo H, Daida H.

Atherosclerosis. 2014 Nov;237(1):374-8. doi: 10.1016/j.atherosclerosis.2014.08.044. Epub 2014 Sep 16.

PMID:
25443876
3.

Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain.

Granér M, Tikkanen E, Rimpilä O, Tikkanen H, Ripatti S, Lokki ML, Nieminen MS, Taskinen MR, Sinisalo J.

Ann Med. 2013 Jun;45(4):322-7. doi: 10.3109/07853890.2013.783996. Epub 2013 May 8.

PMID:
23651064
4.

Development of an immunoassay for the quantification of soluble LR11, a circulating marker of atherosclerosis.

Matsuo M, Ebinuma H, Fukamachi I, Jiang M, Bujo H, Saito Y.

Clin Chem. 2009 Oct;55(10):1801-8. doi: 10.1373/clinchem.2009.127027. Epub 2009 Aug 6.

5.

Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.

Sakai S, Nakaseko C, Takeuchi M, Ohwada C, Shimizu N, Tsukamoto S, Kawaguchi T, Jiang M, Sato Y, Ebinuma H, Yokote K, Iwama A, Fukamachi I, Schneider WJ, Saito Y, Bujo H.

Clin Chim Acta. 2012 Oct 9;413(19-20):1542-8. doi: 10.1016/j.cca.2012.06.025. Epub 2012 Jun 29.

PMID:
22750733
6.

Clinical significance of measuring soluble LR11, a circulating marker of atherosclerosis and HbA1c in familial hypercholesterolemia.

Nohara A, Kobayashi J, Kawashiri MA, Tada H, Inazu A, Jiang M, Mabuchi H, Bujo H.

Clin Biochem. 2014 Sep;47(13-14):1326-8. doi: 10.1016/j.clinbiochem.2014.05.003. Epub 2014 May 22.

PMID:
24859021
7.

Enhanced circulating soluble LR11 in patients with coronary organic stenosis.

Takahashi M, Bujo H, Jiang M, Noike H, Saito Y, Shirai K.

Atherosclerosis. 2010 Jun;210(2):581-4. doi: 10.1016/j.atherosclerosis.2009.12.010. Epub 2009 Dec 16.

PMID:
20047743
8.
9.

Enhanced circulating soluble LR11 in patients with diabetic retinopathy.

Takahashi M, Bujo H, Shiba T, Jiang M, Maeno T, Shirai K.

Am J Ophthalmol. 2012 Jul;154(1):187-92. doi: 10.1016/j.ajo.2012.01.035. Epub 2012 Apr 27.

PMID:
22541650
10.

[Novel biomarker for pathological immature cells--soluble form of LR11].

Bujo H.

Rinsho Byori. 2012 May;60(5):469-76. Japanese.

PMID:
22774576
12.

Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage.

Kume N, Mitsuoka H, Hayashida K, Tanaka M.

J Cardiol. 2011 Jul;58(1):38-45. doi: 10.1016/j.jjcc.2011.03.006. Epub 2011 May 26.

13.

ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes.

Zha Y, Chen Y, Xu F, Li T, Zhao C, Cui L.

Biomed Pharmacother. 2010 Mar;64(3):160-4. doi: 10.1016/j.biopha.2009.09.012. Epub 2009 Nov 5.

PMID:
19944557
14.

Prognostic impact of circulating soluble LR11 on long-term clinical outcomes in patients with coronary artery disease.

Ogita M, Miyauchi K, Kasai T, Tsuboi S, Wada H, Naito R, Konishi H, Dohi T, Tamura H, Okazaki S, Yanagisawa N, Shimada K, Suwa S, Jiang M, Bujo H, Daida H.

Atherosclerosis. 2016 Jan;244:216-21. doi: 10.1016/j.atherosclerosis.2015.11.004. Epub 2015 Nov 6.

PMID:
26687467
15.

Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease.

Matsuo Y, Kubo T, Okumoto Y, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Kitabata H, Hirata K, Imanishi T, Akagi H, Akasaka T.

Eur Heart J Cardiovasc Imaging. 2013 Jan;14(1):43-50. doi: 10.1093/ehjci/jes094. Epub 2012 May 9.

16.

Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein.

Mitsuoka H, Toyohara M, Kume N, Hayashida K, Jinnai T, Tanaka M, Kita T.

J Atheroscler Thromb. 2009 Oct;16(5):586-93. Epub 2009 Sep 3.

17.

Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.

Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H.

Clin Chim Acta. 2014 Mar 20;430:48-54. doi: 10.1016/j.cca.2013.12.039. Epub 2014 Jan 4.

PMID:
24394293
18.

Ang II-stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice.

Jiang M, Bujo H, Ohwaki K, Unoki H, Yamazaki H, Kanaki T, Shibasaki M, Azuma K, Harigaya K, Schneider WJ, Saito Y.

J Clin Invest. 2008 Aug;118(8):2733-46. doi: 10.1172/JCI32381.

19.

Total cholesterol content of erythrocyte membranes levels are associated with the presence of acute coronary syndrome and high sensitivity C-reactive protein.

Yu MM, Xu Y, Zhang JH, Wang CH, Wang XC, Cheng ZP, Xu BL.

Int J Cardiol. 2010 Nov 5;145(1):57-8. doi: 10.1016/j.ijcard.2009.04.018. Epub 2009 May 2.

PMID:
19411120
20.

Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.

Ji Q, Lin Y, Liang Z, Yu K, Liu Y, Fang Z, Liu L, Shi Y, Zeng Q, Chang C, Chai M, Zhou Y.

Cardiovasc Diabetol. 2014 Nov 1;13:145. doi: 10.1186/s12933-014-0145-4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk